Anzeige
Mehr »
Sonntag, 18.01.2026 - Börsentäglich über 12.000 News
Silber bei 90. Gold bei 4.600. Kupfer bei 6. - Top-Aktie im Fokus
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3ERJP | ISIN: US00688A2050 | Ticker-Symbol:
NASDAQ
16.01.26 | 22:00
0,225 US-Dollar
-0,88 % -0,002
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ADIAL PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
ADIAL PHARMACEUTICALS INC 5-Tage-Chart

Aktuelle News zur ADIAL PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiAdial Pharmaceuticals, Inc: Adial Pharmaceuticals Announces Publication of International PCT Patent Application to Protect Core Assets and Extend IP Exclusivity to at least 20451
06.01.ADIAL PHARMACEUTICALS, INC. - 8-K, Current Report1
01.12.25ADIAL PHARMACEUTICALS, INC. - 8-K, Current Report-
26.11.25Adial Pharmaceuticals raises $2.86 million through warrant exercise1
26.11.25Adial Pharmaceuticals, Inc: Adial Pharmaceuticals Announces a Warrant Inducement Transaction for Approximately $2.86 Million in Gross Proceeds1
ADIAL PHARMACEUTICALS Aktie jetzt für 0€ handeln
14.11.25Adial Pharmaceuticals GAAP EPS of -$0.086
14.11.25Adial Pharmaceuticals, Inc: Adial Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update320GLEN ALLEN, Va., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies...
► Artikel lesen
14.11.25ADIAL PHARMACEUTICALS, INC. - 8-K, Current Report-
13.11.25ADIAL PHARMACEUTICALS, INC. - 10-Q, Quarterly Report-
17.10.25Adial Pharmaceuticals, Inc: Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show1
09.10.25Adial completes key validation for alcohol disorder treatment test1
09.10.25Adial Pharmaceuticals, Inc: Adial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution142GLEN ALLEN, Va., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies...
► Artikel lesen
16.09.25ADIAL PHARMACEUTICALS, INC. - 8-K, Current Report1
16.09.25Adial Pharmaceuticals, Inc: Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04276GLEN ALLEN, Va., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies...
► Artikel lesen
16.09.25Adial Pharmaceuticals Highlights Favorable Comments From FDA Meeting For Lead Program In Alcohol Use Disorder2
09.09.25ADIAL PHARMACEUTICALS, INC. - S-8, Securities to be offered to employees in employee benefit plans2
03.09.25Adial Pharmaceuticals receives 180-day Nasdaq extension to meet $1 bid price1
03.09.25ADIAL PHARMACEUTICALS, INC. - 8-K, Current Report1
03.09.25Adial Pharmaceuticals, Inc: Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule1
20.08.25Adial Hails Senate Moves on Trials1
Weiter >>
38 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1